PMC9632690

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, concern about depression was associated with three times the odds of interest in reducing or stopping opioid use (AOR 3.04, 95% CI 1.48-6.22, p = .002) after

Effect: improvement; AOR 3.04; CI: 95% CI: 1.48-6.22

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29

Among PWID whose main drug was an opioid, female gender was associated with more than twice the odds of interest in reducing or stopping opioid use (AOR 2.19, 95% CI 1.11-4.29, p = .023) compared to m

Effect: improvement; AOR 2.19; CI: 95% CI: 1.11-4.29